Clinical outcomes after ventricular tachycardia ablation with or without induction

IF 2.9 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
Benjamin L. Freedman MD , Shu Yang MD , Jonathan W. Waks MD , Andrew Locke MD , Timothy R. Maher MD , Andre d’Avila MD, PhD
{"title":"Clinical outcomes after ventricular tachycardia ablation with or without induction","authors":"Benjamin L. Freedman MD ,&nbsp;Shu Yang MD ,&nbsp;Jonathan W. Waks MD ,&nbsp;Andrew Locke MD ,&nbsp;Timothy R. Maher MD ,&nbsp;Andre d’Avila MD, PhD","doi":"10.1016/j.hroo.2024.10.023","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Substrate mapping may offer a safer alternative to ventricular tachycardia (VT) mapping by avoiding prolonged episodes of VT during catheter ablation. However, VT induction to gauge procedural efficacy is still routinely attempted following substrate ablation, thereby exposing patients to potentially unnecessary hemodynamic risk.</div></div><div><h3>Objective</h3><div>The purpose of this study was to assess the efficacy of VT ablation without VT induction.</div></div><div><h3>Methods</h3><div>Patients with implantable cardioverter-defibrillators who underwent VT ablation between August 2020 and May 2023 were assessed retrospectively. Ablation and induction strategies were determined by operator discretion. Patients with or without attempted VT induction were compared with respect to baseline characteristics and clinical outcomes using Cox and competing risks regression.</div></div><div><h3>Results</h3><div>Eighty-nine patients (median age 68 years; 89% male; 51% infarct-related cardiomyopathy, mean left ventricular ejection fraction 38%) were followed for a median of 16 months after VT ablation. VT induction was attempted in 63% of patients. The 1-year incidence of recurrent VT was 37% and 58% in the noninduction and induction groups, respectively (subhazard ratio 0.55, 95% confidence interval [CI] 0.27–1.09, <em>P</em> = .09). The 1-year incidence of recurrent VT, heart transplant, or death was 42% and 62% in the noninduction and induction groups, respectively (hazard ratio 0.58, 95% CI 0.31–1.11, <em>P</em> = .10).</div></div><div><h3>Conclusion</h3><div>In a single-center study of 89 VT ablations, a noninduction strategy was similar to an induction strategy with respect to VT recurrence, heart transplant, or death at 1 year. Our findings suggest that VT induction, recognized as a risk factor for hemodynamic compromise, can be avoided in some patients without sacrificing procedural efficacy.</div></div>","PeriodicalId":29772,"journal":{"name":"Heart Rhythm O2","volume":"6 2","pages":"Pages 214-223"},"PeriodicalIF":2.9000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Heart Rhythm O2","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666501824003738","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Substrate mapping may offer a safer alternative to ventricular tachycardia (VT) mapping by avoiding prolonged episodes of VT during catheter ablation. However, VT induction to gauge procedural efficacy is still routinely attempted following substrate ablation, thereby exposing patients to potentially unnecessary hemodynamic risk.

Objective

The purpose of this study was to assess the efficacy of VT ablation without VT induction.

Methods

Patients with implantable cardioverter-defibrillators who underwent VT ablation between August 2020 and May 2023 were assessed retrospectively. Ablation and induction strategies were determined by operator discretion. Patients with or without attempted VT induction were compared with respect to baseline characteristics and clinical outcomes using Cox and competing risks regression.

Results

Eighty-nine patients (median age 68 years; 89% male; 51% infarct-related cardiomyopathy, mean left ventricular ejection fraction 38%) were followed for a median of 16 months after VT ablation. VT induction was attempted in 63% of patients. The 1-year incidence of recurrent VT was 37% and 58% in the noninduction and induction groups, respectively (subhazard ratio 0.55, 95% confidence interval [CI] 0.27–1.09, P = .09). The 1-year incidence of recurrent VT, heart transplant, or death was 42% and 62% in the noninduction and induction groups, respectively (hazard ratio 0.58, 95% CI 0.31–1.11, P = .10).

Conclusion

In a single-center study of 89 VT ablations, a noninduction strategy was similar to an induction strategy with respect to VT recurrence, heart transplant, or death at 1 year. Our findings suggest that VT induction, recognized as a risk factor for hemodynamic compromise, can be avoided in some patients without sacrificing procedural efficacy.
有或无诱导的室性心动过速消融后的临床结果
背景基底映射可避免导管消融过程中长期的室性心动过速(VT)发作,从而为室性心动过速(VT)映射提供更安全的替代方案。方法对 2020 年 8 月至 2023 年 5 月间接受 VT 消融术的植入式心律转复除颤器患者进行回顾性评估。消融和诱导策略由操作者自行决定。结果 89名患者(中位年龄68岁;89%为男性;51%为梗死相关性心肌病,平均左室射血分数为38%)在VT消融术后接受了中位16个月的随访。63%的患者尝试了VT诱导。非诱导组和诱导组 VT 1 年复发率分别为 37% 和 58%(亚危险比 0.55,95% 置信区间 [CI]0.27-1.09,P = .09)。在一项对 89 例 VT 消融术进行的单中心研究中,就 1 年后 VT 复发、心脏移植或死亡而言,非诱导组和诱导组的复发率分别为 42% 和 62%(危险比 0.58,95% 置信区间 [CI]0.31-1.11,P = .10)。我们的研究结果表明,VT诱导被认为是血流动力学受损的风险因素,但在不影响手术疗效的情况下,可以避免对某些患者进行诱导。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Heart Rhythm O2
Heart Rhythm O2 Cardiology and Cardiovascular Medicine
CiteScore
3.30
自引率
0.00%
发文量
0
审稿时长
52 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信